CD19 CAR T cells after family donor transplant for leukemia and lymphoma
Tests CD19 CAR T cells after transplant in children with leukemia.
Key facts
- Who runs it
- St. Jude Children's Research Hospital
- Where
- Memphis, United StatesSee the site
- Trial code
- Registry title
- CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 70 people, planned
- Started
- 3 Oct 2026
- Expected to end
- Dec 2035
- Type of study
- Interventional
- Treatments tested
- Anti-Thymocyte Globulin (Rabbit)
- Cyclophosphamide
- Fludarabine
- Thiotepa
- Mesna
- Melphalan
- Filgrastim
- CliniMACS System
- Record updated
- 28 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people up to 21 years old with high-risk CD19-positive leukemia (ALL) who need a stem-cell transplant from a partly compatible family donor.
- Age
- Up to 21 years old.
- Sex
- All sexes can join.
- Disease stage
- High-risk CD19+ B-cell ALL in first or second remission, or any CD19+ B-cell ALL in third or later remission. Any past CNS leukemia must be treated and in CNS remission.
- Earlier treatment
- No earlier donor stem-cell transplant. The trial is for people with no HLA-identical sibling or 12/12 HLA-matched unrelated donor available in time.
- Biomarker or test result
- The leukemia must be CD19-positive.
Main reasons for not taking part
- An HLA-identical sibling or 12/12 matched unrelated donor is available in time
- Another active cancer besides the one being treated
- A prior donor stem-cell transplant
- Pregnancy or breastfeeding
- A severe uncontrolled bacterial, fungal or viral infection
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Recipient
- Age less than or equal to 21 years
- High risk hematologic malignancy where allogeneic transplantation is the current standard of care. This includes (but is not limited to):; High risk CD19+ B cell ALL in CR1 or CR2; Any CD19+ B-cell ALL in CR3 or subsequent
- If prior CNS leukemia, it must be treated and in CNS CR
- Left ventricular ejection fraction > 40%, or shortening fraction ≥ 25%
- Creatinine clearance (CrCl) or glomerular filtration rate (GFR) ≥ 50 ml/min/1.73m2
- Forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing
- Karnofsky or Lansky (age dependent) performance score ≥ 50 (See APPENDIX A)
- Bilirubin ≤ 3 times the upper limit of normal for age
- Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age; Donor
- At least single haplotype matched (≥ 4 of 8) family member
- At least 18 years of age
- HIV negative
- If sexually active, agreement to use birth control until 2 weeks after completion of the mobilization and apheresis procedure
- Regarding donation eligibility, is identified as either:; Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR; Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271
Who cannot take part
- Received a prior allogeneic HCT at any time
- Any other active malignancy other than the one for which this HCT is indicated
- Any severe current uncontrolled bacterial, fungal or viral infection; Donor
- Pregnant, if female is of childbearing potential, negative test must be confirmed by serum or urine pregnancy test within 14 days prior to enrollment
- Pregnant, negative test must be confirmed by serum or urine pregnancy test within 14 days prior to enrollment if female
- Recipient
- Has a suitable HLA-identical sibling or suitable 12/12 (HLA-A, B, C, DRB1, DQB1, and DPB1) HLA-matched unrelated donor available in an appropriate time frame
- If sexually active, agreement to use birth control until 6 months after T cell infusion
- Breast feeding
- If female, breast feeding
Where in United States
- St. Jude Children's Research HospitalMemphis, United StatesContact: Swati Naik, MBBSTaking people
About the trial
What the trial wants to find out
The purpose of this study is to learn more about newer methods of transplanting blood cells donated by a partially matched family member to children with high-risk CD19 positive leukemia ALL.
Read full original descriptionShow less
Primary Objective:
- To assess the safety and feasibility of combining CD19-CAR(Mem) T cells after TCRαβ+/CD19 depleted haploidentical donor transplantation for pediatric patients with relapsed/refractory CD19+ B-cell malignancies.
Secondary Objectives:
* To estimate 1-year post-transplant overall survival, event-free survival, and GVHD-free relapse-free survival (GRFS). * To estimate cumulative incidence of engraftment, acute and chronic GVHD, and immune-related adverse events, including CRS and ICANS.
The group in the trial
- HAPALL TreatmentTreatment being tested
Patients receive a conditioning regimen that will comprise of ATG, Fludarabine, Cyclophosphamide. Melphalan and Thiotepa. Following the conditioning regimen, patients receive infusion of TCRαβ+/CD19 B cell depleted progenitor cell infusion on day 0. Then as early as day + 14 patients will receive the previously manufactured CD19-CAR(Mem) T cell product. Patients will then be monitored for safety and efficacy of the infused CAR T-cell product, Cells for infusion are prepared using the CliniMACS system.
Treatment: Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine, Thiotepa, Mesna, Melphalan, Filgrastim, and CliniMACS System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
- Plain-language title
- CD19 CAR T cells after family donor transplant for leukemia and lymphomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 28 August 2026